Profile
Yuelie Lu worked as an Associate Director of Chemical Development at Lexicon Pharmaceuticals, Inc. and as a Principal Scientist at Amgen, Inc. He also worked as a VP of Pharmaceutical Business Development at Chemspec International Ltd.
from 2009 to 2010.
In 2018 to 2019, he worked as a VP of Chemistry, Manufacturing & Control Operations at Turning Point Therapeutics, Inc. Dr. Lu holds a doctorate degree from Purdue University and undergraduate and graduate degrees from the University of Science & Technology of China.
Former positions of Yuelie Lu
| Companies | Position | End |
|---|---|---|
| TURG POIN | Chief Operating Officer | 2019-06-30 |
| LEXICON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| AMGEN INC. | Corporate Officer/Principal | - |
Chemspec International Ltd.
 Chemspec International Ltd. Chemicals: SpecialtyProcess Industries Chemspec International Ltd. manufactures chemical products. It makes fluorinated chemicals used for the variety of purposes, including the development of other chemicals, as well as in the manufacture of products such as electronics, pharmaceuticals, and pesticides. Its products are used as building blocks for advanced chemicals or used to enhance the performance of the end products of their clients. Its three major market areas are pharmaceutical, agrochemical industries and electronics. It was founded in 1996 and is headquartered in Shanghai, China. | Corporate Officer/Principal | - |
Training of Yuelie Lu
| Purdue University | Doctorate Degree |
| University of Science & Technology of China | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Chemspec International Ltd.
Chemspec International Ltd. Chemicals: SpecialtyProcess Industries Chemspec International Ltd. manufactures chemical products. It makes fluorinated chemicals used for the variety of purposes, including the development of other chemicals, as well as in the manufacture of products such as electronics, pharmaceuticals, and pesticides. Its products are used as building blocks for advanced chemicals or used to enhance the performance of the end products of their clients. Its three major market areas are pharmaceutical, agrochemical industries and electronics. It was founded in 1996 and is headquartered in Shanghai, China. | Process Industries |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Yuelie Lu
